A PET/CT approach to spinal cord metabolism in amyotrophic lateral sclerosis

Cecilia Marini1,2,3 · Angelina Cistaro4 · Cristina Campi5 · Andrea Calvo6,7 · Claudia Caponnetto6,9 · Flavio Mariano Nobili8,9 · Piercarlo Fania4 · Mauro C. Beltrametti10 · Cristina Moglia6,7 · Giovanni Novi8,9 · Ambra Buschiazzo2 · Annalisa Perasso5 · Antonio Canosa6,7 · Carlo Scialò8,9 · Elena Pomposelli2 · Anna Maria Massone5 · Maria Caludia Bagnara11 · Stefania Cammarosano6,7 · Paolo Bruzzi12 · Silvia Morbelli2 · Gianmario Sambuceti2 · Gianluigi Mancardi8,9 · Michele Piana5,10 · Adriano Chiò6,7

Received: 1 April 2016 / Accepted: 8 June 2016 / Published online: 15 July 2016
© The Author(s) 2016. This article is published with open access at Springerlink.com

Abstract

Purpose In amyotrophic lateral sclerosis, functional alterations within the brain have been intensively assessed, while progression of lower motor neuron damage has scarcely been defined. The aim of the present study was to develop a computational method to systematically evaluate spinal cord metabolism as a tool to monitor disease mechanisms.

Methods A new computational three-dimensional method to extract the spinal cord from 18F-FDG PET/CT images was evaluated in 30 patients with spinal onset amyotrophic lateral sclerosis and 30 controls. The algorithm identified the skeleton on the CT images by using an extension of the Hough transform and then extracted the spinal canal and the spinal cord. In these regions, 18F-FDG standardized uptake values were measured to estimate the metabolic activity of the spinal canal and cord. Measurements were performed in the cervical and dorsal spine and normalized to the corresponding value in the liver.

Results Uptake of 18F-FDG in the spinal cord was significantly higher in patients than in controls (p < 0.05). By contrast, no significant differences were observed in spinal cord and spinal canal volumes between the two groups. 18F-FDG uptake was completely independent of age, gender, degree of functional impairment, disease duration and riluzole treatment. Kaplan-Meier analysis showed a higher mortality rate in patients with standardized uptake values above the fifth decile at the 3-year follow-up evaluation (log-rank test, p < 0.01). The independence of this value was confirmed by multivariate Cox analysis.

Conclusion Our computational three-dimensional method enabled the evaluation of spinal cord metabolism and volume and might represent a potential new window onto the pathophysiology of amyotrophic lateral sclerosis.

Keywords PET/CT · Amyotrophic lateral sclerosis · Spinal cord · Neuroimaging
Introduction

Neuroimaging with radionuclide methods allows the evaluation of many features of the central nervous system. However, while there is a large literature on the feasibility of nuclear medicine in the study of the brain, its use in the evaluation of the spinal cord (SC) has scarcely been investigated. This can at least partially be explained by the morphology of this nervous structure whose limited extension has prevented the development of standardized methods to systematically analyze its radioactivity uptake. To overcome this limitation—and to expand functional evaluation to the SC—we have recently developed a computational algorithm able to automatically recognize the spinal canal and SC in coregistered PET/CT images.

In the present study, we tested the accuracy and feasibility of this approach. As a first validation step, the method was applied to a series of patients with amyotrophic lateral sclerosis (ALS). Although this severe neurodegenerative disease actually causes progressive damage to the upper and lower motor neurons [1, 2], its evaluation by PET/CT imaging has been limited to the motor cortex. Several studies have shown the relevance of inflammatory signals in the motor cortex related to microglial activation or lymphocyte/macrophage infiltration [3–9] as possible correlates of disease phenotype [10]. However, virtually none of these studies systematically evaluated SC damage.

Extending the analysis to the lower motor neurons might thus be a new approach to improving our understanding of the heterogeneous nature of ALS. The clinical course of this severe disease is variable with survival usually averaging 3–4 years from symptom onset [11] or more than 10 years in a small number of patients [12]. As a consequence, our computational algorithm and its potential to objectively define the severity of SC involvement might complement the clinical evaluation in defining disease aggressiveness.

Materials and methods

The study included 30 patients (20 men, mean age 66 ± 10 years, median 69 years, range 34–82 years) with definite, probable or probable laboratory-supported spinal onset ALS according to the revised El Escorial criteria [13]. All subjects provided signed informed consent to be entered into the study that was approved by the Ethics Committees of IRCCS AOU San Martino-IST in Genova and of AUO Città della Salute e della Scienza in Torino, Italy. The revised ALS functional rating scale (ALSFRS-R, maximum score 48) [14] was used to evaluate overall patient functional status at the time of the study.

Data obtained in the patients were compared with data from 30 control subjects without any history of neurodegenerative disease, randomly selected from a previously published normalcy database [15] according to a case-control criterion considering, age, sex and scanner used. This registry includes patients who had a negative PET/CT scan 2 years after surgery for a nonulcerated lesion, with a Breslow thickness less than 1 mm and negative sentinel node biopsy. Overall 10-year survival approaches 100% in this population [16]. However, to minimize the possible inclusion of cancer patients, enrolment was delayed by 2 years after scanning so as to include only those subjects who did not have any evidence of relapse or any clinical event during this follow-up period.

PET/CT imaging

All subjects were studied in the early morning after fasting for 12 h. Serum glucose was assessed to ensure a glucose level ≤2 g/l. A bolus injection of FDG was administered (4.8–5.2 MBq/kg body weight) with the patient lying in the supine position in a quiet room and instructed not to move or talk. A three-dimensional (3D) whole-body scan (arms down position) was started 60–75 min after tracer administration using an integrated PET/CT scanner (Hirez, Siemens Medical Solutions; or Discovery, GE Healthcare).

Raw PET data were reconstructed into a 128 × 128 matrix using a 3D iterative reconstruction algorithm (ordered-subsets expectation maximization, three iterative steps, eight subsets). Postfiltering with a 3D gaussian filter and scatter correction were applied, and attenuation correction was performed using the CT data. The resulting resolution was 4.0 mm full-width at half-maximum for both scanners. The two imaging systems were cross-calibrated according to the standard procedures for quality control. In both centres, the PET scanners were periodically calibrated with the same phantom, i.e. a cylinder of 20 cm outer diameter and 20 cm length filled with a solution containing 100 MBq of 18F-FDG that was counted for 1 h to minimize the statistical noise, while images were reconstructed with the same algorithm used for the clinical protocol.

The entire CT dataset was coregistered with the 3D PET images using commercially available software interfaces. For each patient, ideal body weight was calculated according to the conventional formula of Robinson et al. [17]. The spinal canal and SC were segmented from the low-dose CT data acquired during the PET/CT scan to confirm the performance of the analysis in a broad clinical setting.

Image analysis

The different spinal canal and SC districts were defined anatomically considering the cervical segment as the region between the skull base and the plane adjacent to the caudal face of the C7 vertebral body. The dorsal segment was defined as the district between this plane and the one adjacent to the caudal face of D12. The sacral and lumbar canal districts were
a priori considered free from SC and were thus excluded from the analysis.

Images were analysed according to a previously validated method [18, 19] based on generalization of the Hough transform technique for pattern recognition [20]. According to the original definition [21], given a point \( P = (x_P, y_P) \) in the image plane satisfying the equation of a straight line

\[ y = ax + b \]  

(1)

the Hough transform of \( P \) with respect to the class of straight lines, is the straight line of equation

\[ y_P = ax_P + b \]  

(2)

into the parameter space where the two independent real parameters \( a, b \) vary [21]. This definition implies that all points on the line (1) in the image space correspond to lines in the parameter space that all intersect at the point \((a, b)\) uniquely identifying the original line. This correspondence between the image and the parameter spaces holds not only for lines, but also for several classes of algebraic curves. This simple fact inspired the following pattern recognition algorithm for the identification of curves in a digital image:

1. Apply the traditional Canny edge detection algorithm [22] to extract discontinuities.
2. Compute the Hough transforms with respect to the selected family of curves of all points in the image plane highlighted by the edge detection process.
3. Discretize the parameter space into cells whose size is optimized for the specific recognition problem (for the recognition of SC the four-dimensional parameter space is discretized with hypercubes with side equal to 0.02, while for the recognition of the spinal canal the two-dimensional parameter space is discretized with squares with side again 0.02).
4. Construct an accumulator function defined on the discretized parameter space such that for each cell the value of the accumulator function is equal to the number of Hough transforms passing through that cell.
5. Search for the parameter values identifying the cell where the accumulator function reaches its maximum.

We applied this scheme to the recognition of both the spinal canal and the SC districts in whole-body CT images of control subjects and ALS patients. Specifically, the family of curves with three convexities, represented by the equation

\[ C_{a,b} : (x^2 + y^2)^3 = (a(x^2 + y^2) - b(x^3 - 3xy^2))^2, \]  

(3)

was particularly appropriate for the optimal detection of the spinal canal (Fig. 1).

By contrast, the four-parameter family of ellipses expressed in the form

\[ E_{a,b,c,d} : b^2(x-c)^2 + a^2(y-d)^2 - a^2b^2 = 0 \]  

(4)

was the best candidate for identifying the SC district. In agreement with our previous experience [18, 19], visual inspection by an experienced nuclear medicine physician always confirmed the reliability of the segmentation algorithm.

For each CT slice, the two curves identifying the spinal canal and SC were used to create two sets of binary masks with one zero outside and one inside each curve, respectively. These masks were multiplied against the coregistered PET slice in order to digitally extract the metabolic information represented as standardized uptake value (SUV) of local FDG radioactivity [23]. Finally, the average SUVs of both spinal canal and SC were divided by the corresponding average SUV in the liver in order to account for possible differences in scanner sensitivity to obtain the normalized SUVs (NSUVs). NSUVs of the whole SC were computed according to the formula:

\[
SC_{NSUV} = \frac{(C_{NSUV} \times \text{cervical SC volume}) + (D_{NSUV} \times \text{dorsal SC volume})}{\text{cervical SC volume} + \text{dorsal SC volume}},
\]  

(5)

where \( C_{NSUV} \) and \( D_{NSUV} \) indicate the average NSUV of the cervical and dorsal SC segments, respectively.

**Statistical analysis**

All data are reported as means ± SD. Unpaired or paired \( t \) tests were used, as appropriate. Linear regression analysis was performed using the least squares method. A \( p \) value <0.05 was considered significant.

The 30 ALS patients were divided into two groups using the fifth decile NSUV (0.67). Survival of these two groups was analysed using the Kaplan-Meier method and compared using the log-rank test. To assess the prognostic relevance of the NSUV of the SC (SC_NSUV), a set of univariate and multivariate Cox proportional hazard models were fitted to the data. In the univariate analysis, the incidence of death was modelled as a function of each of the following variables: age, sex, time from ALS diagnosis to PET/CT scan, riluzole therapy, ALS functional score and average SC_NSUV (below and above the fifth decile). Then all six variables were tentatively included in a multivariate Cox model by means of a step-down (backward) procedure, based on the likelihood ratio test: variables with a \( p \) value >0.1 were removed from the model. Proportionality assumptions were assessed as previously described [24].
Results

Clinical characteristics of the patients and controls

The main clinical findings in the ALS patients and control subjects are shown in Table 1. According to the case-control selection criterion, age, sex, and ideal body weight were similar in the two groups. Similarly, serum glucose levels were comparably low in the two groups (Table 1). The ALSFRS-R score, updated for each patient on the day of imaging, ranged from 20 to 46/48.

The time from ALS onset to PET/CT imaging was 18 ± 15 months (range 2 – 69 months, median 16 months). The patients were followed up for 1 – 36 months after imaging (median 14 months). During this period, 13 patients died from respiratory complications (Table 1).

Shape and volume of spinal canal and spinal cord

The spinal canal profile significantly changed across the whole stack of CT images. However, the Hough transform method allowed the parameters of the curve with three convexities to automatically change allowing the curve to optimally adapt itself to the profile. The profile of the SC could be recognized by the Hough transform of an ellipse for all spinal districts. Further, the parameters of such an ellipse changed less than 10% in the cervical district and less than 12% in the dorsal district. This formulation did not change throughout the
spinal districts and the SC was segmented by adjusting the numerical parameters.

As shown in Fig. 2, the disease did not affect the anatomical features of the spinal canal or the SC. The spinal cord volume was similar in ALS patients and in control subjects, both in the cervical district (32.08 ± 7.12 mL vs. 31.36 ± 5.99 mL, respectively, \( p = 0.79 \)) and in the dorsal district (65.60 ± 10.09 mL vs. 68.84 ± 12.61 mL, respectively, \( p = 0.10 \); Fig. 2a–e). The extracted SC volume was also similar in patients and control subjects both in the cervical segment (13.99 ± 1.42 mL vs. 13.53 ± 1.60 mL, respectively, \( p = 0.47 \), ns) and in the dorsal segment (32.60 ± 3.22 mL vs. 32.81 ± 4.25 mL, respectively, \( p = 0.56 \); Fig. 2b). As for the spinal canal, ideal body weight was directly correlated with overall SC volume in control subjects, but the significance of this relationship was lower in ALS patients (Fig. 2f).

### Spinal canal and spinal cord metabolic activity

On visual inspection, the radioactivity distribution within the SC was relatively homogeneous without any focal areas of enhanced uptake in both control subjects and ALS patients (Fig. 3a, b). As shown in Fig. 3c–e, the average NSUV was not significantly different between the two groups in the whole spinal canal or in the cervical and dorsal districts. As expected, the average NSUV was significantly lower than the corresponding SC_NSUV in the same districts in both groups (Fig. 3c). By contrast, the radioactivity distribution in the SC showed a different pattern. FDG uptake in the SC was higher in ALS patients than in controls. This difference in FDG uptake between the groups was statistically significant for the whole SC (NSUV 0.82 ± 0.28 in ALS patients vs. 0.70 ± 0.14 in controls, \( p < 0.05 \)) and for the cervical segment (NSUV 0.99 ± 0.37 vs. 0.85 ± 0.20, respectively; \( p < 0.05 \), Fig. 3c, d), but not for the dorsal segment (NSUV 0.72 ± 0.24 vs. 0.62 ± 0.18, respectively; \( p = 0.08 \); Fig. 3e). Interestingly, the effect of ALS on FDG accumulation in the SC was independent of demographic and clinical variables. In fact, SC_NSUV did not correlate with age, sex, ALSFRS-R score, time elapsed from diagnosis to PET/CT or riluzole treatment (Fig. 4).

### Spinal cord metabolic pattern and patient outcomes

The potential prognostic value of metabolic information was suggested by the observation that the 13 patients who died showed a higher SC_NSUV than the 17 patients who were still alive at 36 months (0.71 ± 0.26 vs. 0.55 ± 0.16, respectively, \( p < 0.05 \); Fig. 4f). This result was confirmed by Kaplan-Meier analysis showing that the 16 patients with NSUV above the fifth decile had a significantly higher mortality rate than those with NSUV below the fifth decile at 36 months after PET/CT imaging (log-rank test, \( p < 0.01 \); Fig. 5).

In the univariate analysis, the only predictive variable for overall survival was SC_NSUV (Table 2). The multivariate analysis confirmed the independent prognostic value of the SC metabolic pattern (hazard ratio, HR, 24.3, 95 % confidence interval, CI, 2.2 – 262.8) although the strength of the association needs to be confirmed in a large sample. Prognosis was not associated with age, ALSFRS-R score, time from diagnosis to PET scanning or the presence/absence of riluzole treatment. A significantly increased risk of death was found for male gender (HR 4.43, 95% CI 0.87–22.5), and with borderline significance with age (HR 1.055) and ALSFRS-R score (HR 0.82), but there was no trend in risk with increasing or decreasing age or ALSFRS-R score. On the other hand, there was no significant difference in ALSFRS-R score at the time of PET scanning between those who had died and those who were still alive at 36 months (39.61 ± 3.5 vs. 38.76 ± 6.66, \( p = 0.7 \)).

### Discussion

The present study is the first attempt to estimate the metabolic pattern of the spinal canal and SC from whole-body PET/CT images. The results obtained indicate that this computational approach might be a new method for exploring the status of...
the SC in different conditions, besides its potential to complement the routine analysis of ALS patients.

Recognition and measurement of spinal canal and spinal cord by CT analysis

Estimation of the canal space throughout the whole spine was based on the assumption that compact bone is the human tissue with the highest X-ray attenuation coefficient and can thus be easily identified and extracted in each CT slice. This computational approach is commonly used in commercially available software for 3D representation of the skeleton, and its potential has been previously validated in our laboratory for the characterization of intraosseous volume and bone marrow metabolic activity [15, 25, 26]. However, thresholding the Hounsfield values on the CT images is not effective in this application since the spinal canal is not directly surrounded by osseous tissue in all slices. To overcome this problem, we developed a pattern recognition method based on the Hough transform that permitted determination of canal shape also in segments between the different vertebral bodies. This approach permitted extraction of PET data and analysis of FDG uptake throughout the whole SC in a systematic fashion.

FDG and spinal cord involvement in ALS

As a first validation step, we applied this method to a cohort of ALS patients. This model fitted our purpose due to the pathological evidence of significant damage to the SC neurons [1, 2]. By contrast, spinal onset ALS was associated with a slight yet significant increase in SC uptake of FDG. Several considerations support the concept that this finding reflects an increased metabolism of SC structures. First, the increase in FDG uptake was most evident in the cervical spine segments.
Secondly, it was not related to abnormal regulation of serum glucose levels [27]. Finally, the difference between controls and ALS patients virtually disappeared when the whole spinal canal was considered, most likely because of both the smoothing effect of the large volume and the spillover of radioactivity uptake into surrounding outside tissues.

The increased FDG uptake in ALS SC at least partially conflicts with the expected reduction in tissue metabolic rate caused by the neuronal loss that has been described not only in the motor cortex but also in the anterior horns of the SC in ALS patients. Similarly, it partially disagrees with the emerging prognostic value of frontal hypometabolism in subgroups of ALS patients [4, 5, 28]. Nevertheless, it has been extensively documented in the literature that neuroinflammation is a key-signalling event in ALS [10]. This concept originated from pathology studies showing activation of microglia and astrocytes, as well as the presence of lymphocytes and macrophages in post-mortem tissue from the motor cortex and SC of both patients and experimental models of ALS [29, 30]. As a common interpretation, these studies suggested that activated microglia might accumulate within the degenerating areas and might contribute to propagating and sustaining the tissue damage through the release of free radicals and other neurotoxic substances such as glutamate [30–32]. More recently, this mechanism has been shown to also occur in the early disease phases. In fact, different studies have shown inflammatory microglial activation in various cortical areas of ALS patients using PET imaging and different tracers targeting the translocator protein TSPO [6–8]. In this line, our observation of a relative increase in SC FDG uptake might extend the previously documented pattern of motor cortex damage in ALS to lower motor neurons and might reflect inflammatory mechanisms rather than the expected consequences of motor neuron loss and subsequent SC atrophy.

FDG uptake cannot be considered per se a specific marker of microglia activation. Nevertheless, the relevance of inflammatory mechanisms on ALS progression is supported by the follow-up evaluation. Indeed, the Kaplan-Meier analysis indicated that higher FDG uptake significantly predicted a higher mortality rate. The multivariate analysis confirmed this finding and showed the independent prognostic value of SC metabolism. The observed difference in prognosis between patients with high and low FDG uptake was striking (HR 24). Nevertheless, the effective clinical potential of SC FDG
Fig. 4 a, c, e  Linear regression analysis of the relationship between spinal cord (SC) NSUV and patient age (a), time between diagnosis and imaging (c) and revised ALS functional rating scale (ALSFR-S) score (e). b, d, f The spinal cord metabolic pattern (in terms of NSUV) was not significantly different between male (M) and female (F) patients (b), or between those treated and those not treated with riluzole (d), but SC NSUV was significantly higher in patients who had died (Nonsurvivors) than in those who were still alive (Survivors) at the end of the 36-month follow-up period (f). *p < 0.05

Fig. 5 Kaplan-Meier curves showing overall survival in patients with SC_NSUV above and below the fifth decile. High FDG uptake in the whole spinal cord was associated with a higher mortality rate.
Table 2  Prediction of death

| Variable                          | Outcome results       | Univariate analysis | Multivariate analysis |
|----------------------------------|-----------------------|---------------------|----------------------|
|                                  | No. of patients   | No. of deaths | Mortality rate (%) | Hazard ratio | 95 % confidence interval | p value | For heterogeneity | Hazard ratio | 95 % confidence interval | p value |
| Age (three categories)           |                       |                   |                     |               |                         |         |                   |               |                         |         |
| ≤63 years                        | 10                    | 3                  | 30                  | 1 (reference) | –                        | 0.213   | 0.810             | 1 (reference) | –                        | 0.055   | 0.226 |
| 64 – 72 years                    | 10                    | 4                  | 40                  | 3.20          | 0.74 – 13.84              |         |                   | 7.45          | 1.20 – 46.37             |         |
| ≥73 years                        | 10                    | 6                  | 60                  | 1.22          | 0.24 – 6.09               |         |                   | 6.56          | 0.45 – 95.11             |         |
| ALS score (three categories)     |                       |                   |                     |               |                         |         |                   |               |                         |         |
| ≤38                              | 10                    | 4                  | 40                  | 1 (reference) | –                        | 0.323   | 0.280             | 1 (reference) | –                        | 0.082   | 0.374 |
| 39 – 42                          | 10                    | 4                  | 40                  | 1.39          | 0.35 – 5.51              |         |                   | 2.06          | 0.36 – 11.64             |         |
| ≥43                              | 10                    | 5                  | 50                  | 0.43          | 0.09 – 1.98              |         |                   | 0.30          | 0.04 – 2.15              |         |
| Time from diagnosis to PET/CT (three categories) |       |                   |                     |               |                         |         |                   |               |                         |         |
| ≤9 months                        | 9                     | 6                  | 67                  | 1 (reference) | –                        | 0.367   | 0.240             | –             | –                        | 0.86    | –    |
| 10 – 19 months                   | 14                    | 3                  | 21                  | 0.41          | 0.10 – 1.74              |         |                   | –             | –                        |         |
| ≥20 months                       | 7                     | 4                  | 57                  | 0.45          | 0.11 – 1.86              |         |                   | –             | –                        |         |
| Riluzole treatment               |                       |                   |                     |               |                         |         |                   |               |                         |         |
| No                               | 9                     | 4                  | 44                  | 1 (reference) | –                        | 0.488   | –                  | –             | –                        | 0.51    | –    |
| Yes                              | 21                    | 9                  | 43                  | 1.54          | 0.45 – 5.27              |         |                   | –             | –                        |         |
| Sex                              |                       |                   |                     |               |                         |         |                   |               |                         |         |
| Female                           | 10                    | 4                  | 40                  | 1 (reference) | –                        | 0.272   | –                  | 1 (reference) | –                        | 0.049   | –    |
| Male                             | 20                    | 9                  | 45                  | 2.02          | 0.54 – 7.56              |         |                   | 4.43          | 0.87 – 22.55             |         |
| Average normalized spinal cord SUV (>5th decile) |       |                   |                     |               |                         |         |                   |               |                         |         |
| ≤0.67                            | 16                    | 3                  | 19                  | 1 (reference) | –                        | 0.003   | –                  | 1 (reference) | –                        | 0.01    | –    |
| >0.67                            | 14                    | 10                 | 71                  | 6.87          | 1.50 – 31.58             |         |                   | 24.3          | 2.25 – 262.77            |         |

---

a Total 30 patients, 13 died, overall mortality rate 43 %

b Removed from the final Cox multivariate model (p > 0.1)
uptake in outcome prediction could not be assessed in the present study because of the limited number of patients, the retrospective nature of the evaluation and particularly the fact that this hypothesis was generated by our study and needs to be validated on independent datasets.

The fact that there were 17 patients censored before death does not imply any risk of bias because these were not patients lost to follow-up, but patients with recent enrolment. Furthermore, they were similarly distributed in the two groups of patients with SUV below and above the median. A similar consideration also applies to the exclusion of patients with bulbar onset disease: this decision – justified by the focus of our computational algorithm on SC metabolism – prevents the ability to define the clinical value of this information. Finally, the relatively small number of patients studied together with the exclusion of subjects with bulbar onset ALS prevented verification of the potential added value of SC metabolism with respect to brain FDG uptake. Nevertheless, if confirmed in larger prospective studies, the prognostic significance of SC metabolic pattern would indicate a relevant role for SC inflammatory response in ALS progression.

In conclusion, the present study showed the potential of Hough transform in delineating the spinal canal and SC in clinical PET/CT scanning. As a first validation step, this method was applied to a cohort of ALS patients as a model of pathologically confirmed damage to the SC neurons. However, its use can obviously be extended to different conditions in which the possibility of extracting the spinal canal and its contents might be a useful tool to precisely evaluate the site of SC injury from whatever cause and particularly to improve the accuracy in monitoring its evolution. In this setting, the proposed computational approach to PET/CT images would permit the limitations of visual inspection to be overcome, limitations that have so far hampered the evaluation of SC damage in patients with inflammatory diseases [33], posttraumatic conditions [34], cancer infiltration [35] or autoimmune/autotoxicity disorders [36]. Similarly, its use in combination with tracers selectively targeting specific neuronal functions might contribute to the understanding of SC involvement in different diseases.

As far as ALS is concerned, the availability of this biomarker and its operator-independent nature could be invaluable for the development of new therapeutic approaches, especially in early phase clinical trials in which current entry criteria that consider only phenotype, disability severity and disease duration markedly hamper the correct identification of target patients.

Acknowledgments The study was partially supported by Research Grant CNR Interomics flagship programme 2015 (granted to Cecilia Marini), PAR FAS 2007–2013 programme (to Michele Piana), and ARISLA Foundation Ice-bucket programme 2015 (granted to Gianmario Sambuceti).

Compliance with ethical standards
Conflicts of interest None.

Ethical approval All procedures performed were in accordance with the ethical standards of the institutional and national research committees and with the principles of the 1964 Declaration of Helsinki and its later amendments.

Informed consent All patients provided signed informed consent to be entered into the study that was approved by the Ethics Committees of IRCCS AOU San Martino IST in Genova and of AUO Città della Scienza in Torino, Italy.

Open Access This article is distributed under the terms of the Creative Commons Attribution 4.0 International License (http://creativecommons.org/licenses/by/4.0/), which permits unrestricted use, distribution, and reproduction in any medium, provided you give appropriate credit to the original author(s) and the source, provide a link to the Creative Commons license, and indicate if changes were made.

References
1. Rowland LP, Shneider NA. Amyotrophic lateral sclerosis. N Engl J Med. 2001;344:1688–700.
2. Chiò A, Pagani M, Agosta F, Calvo A, Cistaro A, Filippi M. Neuroimaging in amyotrophic lateral sclerosis: insights into structural and functional changes. Lancet Neurol. 2014;13:1228–40.
3. Pagani M, Chiò A, Valentini MC, Öberg J, Nobili F, Calvo A, et al. Functional pattern of brain FDG-PET in amyotrophic lateral sclerosis. Neurology. 2014;83:1067–74.
4. Cistaro A, Pagani M, Montuschi A, Calvo A, Moglia C, Canosa A, et al. The metabolic signature of C9ORF72-related ALS: FDG PET comparison with nonmutated patients. Eur J Nucl Med Mol Imaging. 2014;41:844–52.
5. Cistaro A, Valentini MC, Chiò A, Nobili F, Calvo A, Moglia C, et al. Brain hypermetabolism in amyotrophic lateral sclerosis: a FDG PET study in ALS of spinal and bulbar onset. Eur J Nucl Med Mol Imaging. 2012;39:251–9.
6. Corcia P, Tauber C, Vercoullie J, Arlicot N, Prunier C, Praline J, et al. Molecular imaging of microglial activation in amyotrophic lateral sclerosis. PLoS One. 2012;7:e52941.
7. Zürcher NR, Loggia ML, Lawson R, Chonde DB, Izquierdo-Garcia D, Yasek JE, et al. Increased in vivo glial activation in patients with amyotrophic lateral sclerosis: assessed with [(11)C]-PBR28. Neuroimage Clin. 2015;7:409–14.
8. Turner MR, Hammers A, Al-Chalabi A, Shaw CE, Andersen PM, Brooks DJ, et al. Cortical involvement in four cases of primary lateral sclerosis using [(11)C]-flumazenil PET. J Neurol. 2007;254:1033–6.
9. Brettschneider J, Toledo JB, Van Deerlin VM, Elman L, McCluskey L, Lee VM-Y, et al. Microglial activation correlates with disease progression and upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS One. 2012;7:e39216.
10. Philips T, Robberecht W. Neuroinflammation in amyotrophic lateral sclerosis: role of glial activation in motor neuron disease. Lancet Neurol. 2011;10:253–63.
11. Turner MR, Bakker M, Sham P, Shaw CE, Leigh PN, Al-Chalabi A. Prognostic modelling of therapeutic interventions in amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2002;3:15–21.
12. Turner MR, Parton MJ, Shaw CE, Leigh PN, Al-Chalabi A. Prolonged survival in motor neuron disease: a descriptive study of the King’s database 1990–2002. J Neurol Neurosurg Psychiatry. 2003;74:995–7.

13. Brooks BR, Miller RG, Swash M, Munsat TL. El Escorial revisited: revised criteria for the diagnosis of amyotrophic lateral sclerosis. Amyotroph Lateral Scler Other Motor Neuron Disord. 2000;1:293–9.

14. Cedarbaum JM, Stambler N, Malta E, Fuller C, Hilt D, Thurmond B, et al. The ALSFRS-R: a revised ALS functional rating scale that incorporates assessments of respiratory function. BDNF ALS Study Group (Phase III). J Neurol Sci. 1999;169:13–21.

15. Sambuceti G, Brignone M, Marini C, Massollo M, Fiz F, Morbetti S, et al. Estimating the whole bone-marrow asset in humans by a computational approach to integrated PET/CT imaging. Eur J Nucl Med Mol Imaging. 2012;39:1326–38.

16. Elder DE. Thin melanoma. Arch Pathol Lab Med. 2011;135:342–6.

17. Robinson JD, Lupkiewicz SM, Palenik L, Lopez LM, Ariet M. Determination of ideal body weight for drug dosage calculations. Am J Hosp Pharm. 1983;40:1016–9.

18. Massone AM, Perasso A, Campi C, Beltrametti MC. Profile detection in medical and astronomical images by means of the Hough transform of special classes of curves. J Math Imaging Vis. 2014;51:296–310.

19. Perasso A, Campi C, Massone AM, Beltrametti MC. Spinal canal and spinal marrow segmentation by means of the Hough transform of special classes of curves. In: Murino V, Puppo E (editors) Image analysis and processing – ICIAP 2015, Lecture Notes in Computer Science, vol. 9279, Cham: Springer; p. 590–600.

20. Beltrametti MC, Massone AM, Piana M. Hough transform of special classes of curves. SIAM J Imaging Sci. 2013;6:391–412.

21. Hough PVC. Method and means for recognizing complex patterns. US Patent 3,069,654, 18 Dec 1962.

22. Camm J. A computational approach to edge detection. IEEE Trans Pattern Anal Mach Intell. 1986;8:679–98.

23. Thie JA. Understanding the standardized uptake value, its methods, and implications for usage. J Nucl Med. 2004;45:1431–4.

24. Grambsch PM, Therneau TM. Proportional hazards tests and diagnostics based on weighted residuals. Biometrika. 1994;81:515–26.

25. Fiz F, Marini C, Piva R, Miglino M, Massollo M, Bongioanni F, et al. Adult advanced chronic lymphocytic leukemia: computational analysis of whole-body CT documents a bone structure alteration. Radiology. 2014;271:805–13.

26. Fiz F, Marini C, Campi C, Massone AM, Podestà M, Bottone G, et al. Allogeneic cell transplant expands bone marrow distribution by colonizing previously abandoned areas: an FDG PET/CT analysis. Blood. 2015;125:4095–102.

27. Lekoubou A, Matsia TE, Sobngwi E, Kengne AP. Effects of diabetes mellitus on amyotrophic lateral sclerosis: a systematic review. BMC Res Notes. 2014;7:171.

28. Irwin DJ, McMillan CT, Bretschneider J, Libon DJ, Powers J, Rascovsky K, et al. Cognitive decline and reduced survival in C9orf72 expansion frontotemporal degeneration and amyotrophic lateral sclerosis. J Neurol Neurosurg Psychiatry. 2013;84:163–9.

29. McCombe PA, Henderson RD. The role of immune and inflammatory mechanisms in ALS. Curr Mol Med. 2011;11:246–54.

30. Troost D, Van den Oord JJ, Vianney de Jong JM. Immunohistochemical characterization of the inflammatory infiltrate in amyotrophic lateral sclerosis. Neuropathol Appl Neurobiol. 1990;16:401–10.

31. Kawamata T, Akiyama H, Yamada T, McGeer PL. Immunologic reactions in amyotrophic lateral sclerosis brain and spinal cord tissue. Am J Pathol. 1992;140:691–707.

32. Lampson LA, Kushner PD, Sobel RA. Major histocompatibility complex antigen expression in the affected tissues in amyotrophic lateral sclerosis. Ann Neurol. 1990;28:365–72.

33. Dong A, Zuo C, Zhang P, Lu J, Bai Y. MRI and FDG PET/CT findings in 3 cases of spinal infectious arachnoiditis. Clin Nucl Med. 2014;39:900–3.

34. van Middendorp JJ, Goss B, Urquhart S, Atresh S, Williams RP, Schuetz M. Diagnosis and prognosis of traumatic spinal cord injury. Global Spine J. 2011;1:1–8.

35. Intriglio B, Danús M, Añaños M, Trampal C, Montero M, Calvo N. 18F-FDG PET detection of spinal leptomeningeal metastases from cerebral glioblastoma multiforme. Eur J Nucl Med Mol Imaging. 2011;38:1392.

36. Levin A, Kasem S, Mader R, Naparstek Y, Friedman G, Ben-Yehuda A. Wegener granulomatosis with back pain, periaortitis, and dural inflammation developing while receiving monthly cyclophosphamide. J Clin Rheumatol. 2006;12:294–7.